Table 2.

Univariate and multivariate analysis for predictor of early death (<6 mo) in the non-ASCT population

Univariate analysisMultivariate analysis
OR95% CIPOR95% CIP
Age ≥65, y 1.0 0.7-1.3 .83 NI 
Male 1.2 0.9-1.6 .23 NI 
>2 organs involved 1.5 1.1-2.1 <.001 1.6 1.1-2.5 .02 
dFLC ≥18 mg/dL 3.0 2.1-4.3 <.001 2.1 1.4-3.3 <.001 
BMPCs ≥10% 1.4 1.03-1.8 .02 NS 
eGFR <30 mL/min per 1.73 m2 0.7 0.5-1.1 .13 NI 
Mayo 2004 stage       
 I Reference   Reference   
 II 3.1 1.1-13.3 .03 2.0 0.7-8.9 .22 
 III 11.7 4.2-48.8 <.001 6.1 2.1-26.4 <.001 
NT-proBNP > 8500 pg/mL 3.4 2.4-4.9 <.001 2.0 1.3-3.0 <.001 
Treatment category       
 MDex Reference   Reference   
 MP 2.1 1.4-3.1 <.001 2.1 0.8-5.6 .13 
 Bortezomib-based 1.3 0.9-1.8 .21 1.5 1.02-2.3 .03 
 IMiD-based 1.3 0.7-2.2 .46 1.5 0.7-3.3 .28 
 Dexamethasone alone 3.7 1.9-7.2 <.001 3.4 1.01-11 .047 
Univariate analysisMultivariate analysis
OR95% CIPOR95% CIP
Age ≥65, y 1.0 0.7-1.3 .83 NI 
Male 1.2 0.9-1.6 .23 NI 
>2 organs involved 1.5 1.1-2.1 <.001 1.6 1.1-2.5 .02 
dFLC ≥18 mg/dL 3.0 2.1-4.3 <.001 2.1 1.4-3.3 <.001 
BMPCs ≥10% 1.4 1.03-1.8 .02 NS 
eGFR <30 mL/min per 1.73 m2 0.7 0.5-1.1 .13 NI 
Mayo 2004 stage       
 I Reference   Reference   
 II 3.1 1.1-13.3 .03 2.0 0.7-8.9 .22 
 III 11.7 4.2-48.8 <.001 6.1 2.1-26.4 <.001 
NT-proBNP > 8500 pg/mL 3.4 2.4-4.9 <.001 2.0 1.3-3.0 <.001 
Treatment category       
 MDex Reference   Reference   
 MP 2.1 1.4-3.1 <.001 2.1 0.8-5.6 .13 
 Bortezomib-based 1.3 0.9-1.8 .21 1.5 1.02-2.3 .03 
 IMiD-based 1.3 0.7-2.2 .46 1.5 0.7-3.3 .28 
 Dexamethasone alone 3.7 1.9-7.2 <.001 3.4 1.01-11 .047 

Boldface indicates significance at P < .05.

CI, confidence interval; OR, odds ratio; NI, not included; NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal